Aurinia Pharmaceuticals (AUPH) Reports In-Line Q2 EPS, narrows guidance

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $57.2 million versus the consensus estimate of $54.25 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2024 revenue of $210-220 million, versus the consensus of $227.1 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• Netflix (NFLX) call put ratio 2.3 calls to 1 put
• Increasing unusual put option volume: OSS CTSH PZZA BFLY CDNS WMB KD DFTX CAN HIVE SOC WYFI SIMO